A. Keith Stewart

Mayo Clinic

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Initial genome sequencing and analysis of multiple myeloma”.

Initial genome sequencing and analysis of multiple myeloma

Nature(2011)10.1038/nature09837

N/A

1.1DataRank · unranked

1438 citations

Michael S. Lawrence, Jonathan J. Keats, Kristian Cibulskis, Carrie Sougnez, Anna C. Schinzel +51 more

Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity

Molecular Cancer Research(2020)10.1158/1541-7786.mcr-19-1026

N/A

0DataRank · unranked

38 citations

Yuan Xiao Zhu, Laura A. Bruins, Cecília Bonolo de Campos, William Stewart, Esteban Braggio +2 more

“Direct to Drug” screening as a precision medicine tool in multiple myeloma

Blood Cancer Journal(2020)10.1038/s41408-020-0320-7

N/A

0DataRank · unranked

24 citations

Nathalie Meurice, Joachim L. Petit, Alysia Polito, Yuan Xiao Zhu, Panwen Wang +19 more

Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e19136

N/A

0DataRank · unranked

5 citations

Fengmin Zhao, Ju‐Whei Lee, Fangxin Hong, Edward H. Ip, Ilana F. Gareen +9 more

Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e19132

N/A

0DataRank · unranked

3 citations

John Devin Peipert, Ju‐Whei Lee, Fangxin Hong, Edward H. Ip, Ilana F. Gareen +15 more

Prevalence and significance of clonal hematopoiesis of indeterminate prognosis (CHIP) in multiple myeloma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8542

N/A

0DataRank · unranked

2 citations

Betsy LaPlant, Shaji Kumar, Kimbery Henderson, Angela Dispenzieri, Terra L. Lasho +3 more

Transcriptional profiles define drug refractory disease in myeloma

eJHaem(2022)10.1002/jha2.455

N/A

0DataRank · unranked

3 citations

Laura A. Bruins, Xianfeng Chen, Chang‐Xin Shi, Cecília Bonolo de Campos, Nathalie Meurice +7 more

Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma

Blood Cancer Journal(2023)10.1038/s41408-023-00851-5

N/A

0DataRank · unranked

9 citations

Erik Jessen, Neeraj Sharma, Hongwei Tang, James B. Smadbeck, Mark D. Long +13 more

Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)

Leukemia(2024)10.1038/s41375-024-02363-y

N/A

0DataRank · unranked

1 citations

Huihuang Yan, Suganti Shivaram, Stacey L. Lehman, Neeraj Sharma, James B. Smadbeck +21 more